RetinalGenix Technologies (RTGN) Osake Kurssi

RetinalGeniX Technologies, Inc. operates as a medical device company. The company is headquartered in Petaluma, California and currently employs 0 full-time employees. The company went IPO on 2022-01-07. The firm is focused on developing technologies to screen, monitor, diagnose and treat ocular, optical, and sight-threatening disorders. The firm is engaged to treat vision loss and blindness due to diabetic retinopathy and maculopathy through two devices: Retinal Imaging Screening Device, a portable, retinal imaging system providing a 200-degree field of view without requiring pupil dilation; and RetinalCam, a home monitoring retinal imaging device and physician alert system offering real-time communication with physicians available 24/7. RetinalCam, is anticipated to have the capability to be used by patients in a variety of locations, including at home, primary care centers, emergency rooms and telehealth centers and nursing homes. Its Retinal Imaging Screening Device technology enables high-risk individuals to send their physician digitized retinal images and stream video easily from their homes.